Jobs
-
Vistagen has announced that the Phase 3 PALISADE-4 public speaking challenge study of intranasal fasedienol (PH94B) for the treatment of social anxiety disorder failed to meet its primary endpoint. In December 2025, the company announced… Read more . . .
-
Insmed has hired former Johnson & Johnson executive Samuele Butera as Senior VP, General Manager, Global Respiratory, the company said. Butera previously served in executive positions at Sandoz and Novartis before joining Johnson & Johnson,… Read more . . .
-
Canadian biotech Zymeworks has agreed to pay $17 per share, a total of approximately $929 million, to acquire Theravance Biopharma, the companies have announced. The deal, which is subject to approval by Theravance shareholders, is… Read more . . .
-
The European Innovation Council Fund, Invest-NL, Gates Foundation, and ClavystBio are among those contributing to a €40 million financing to support development of Leyden Laboratories’ antiviral nasal sprays the company said. Since the beginning of… Read more . . .
-
University of St Andrews spin out Pneumagen has reorganized as a US-based company called NorthLinks Bio, the company said, though research will continue in Scotland. Pneumagen CEO Douglas Thomson has joined the board of the… Read more . . .
-
MannKind Corporation announced that a grant from Breakthrough T1D (formerly JDRF) will be used to support the Phase 2 INHALE-1ST trial of Afrezza in children aged 10 and up with a recent Type 1 diabetes diagnosis, which was initiated earlier… Read more . . .
-
Turin, Italy -based Kither Biotech says that a Phase 1 clinical study of its KIT2014 inhaled PDE3/4 inhibitor successfully demonstrated that the nebulized formulation was safe and well tolerated, with very limited systemic exposure. The… Read more . . .
-
SpliSense announced that it has secured up to $13 million in new funding from the Cystic Fibrosis Foundation to support an ongoing Phase 2 trial of SPL84 inhaled antisense oligonucleotide for the treatment of cystic… Read more . . .
-
According to DPI developer Iconovo, the company has now signed a strategic collaboration deal with CDMO Lonza for development of spray dried formulation of inhaled biologics. In January 2025, Iconovo said that Lonza would develop spray dried… Read more . . .
-
The FDA announced that it has approved an Rx to OTC switch for Amphastar Pharmaceutical’s Rextovy 4 mg naloxone nasal spray. Amphastar’s naloxone nasal spray was initially approved for the treatment of opioid overdose by… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK